OncoMatch/Clinical Trials/NCT05632380
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Is NCT05632380 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies C-CAR088 for multiple myeloma.
Treatment: C-CAR088 — This is a phase I/II, single-arm, open-lable study of autologous stem cell transplantation in combination with C-CAR088, an autologous BCMA CAR-T cell product, for patients with ulta high-risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based treatment with or without the presence of multiple high-risk cytogenetic features.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: VRD-based treatment (bortezomib, lenalidomide, dexamethasone) — front line
failed or unsatisfied responses to front line VRD-based treatment
Cannot have received: allogenic HSCT
Prior allogenic HSCT
Cannot have received: autologous stem cell transplant
Prior ... ASCT
Cannot have received: CAR-T cell therapy
Previous CAR-T cell treatment, genetically modified T-cell therapies or BCMA-directed treatment history
Cannot have received: BCMA-directed treatment
Previous CAR-T cell treatment, genetically modified T-cell therapies or BCMA-directed treatment history
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify